Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677297 | 1.00 | MAPT (0.47) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL30677385 | 0.89 | GSK3B (0.45) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL31576372 | 0.89 | GSK3B (0.45) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL30677394 | 0.87 | MAPT (0.44) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL31576452 | 0.87 | MAPT (0.44) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL31576454 | 0.83 | CYP2C9 (0.49) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL30677303 | 0.83 | CYP2C9 (0.49) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL30677279 | 0.82 | MAPT (0.43) | MAPTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL31576407 | 0.81 | KDM4E (0.58) | MAPTSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL30676743 | 0.81 | KDM4E (0.58) | MAPTSMN1; SMN2RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | MAPT 3575/4885SMN1; SMN2 835/4885MEN1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.